Q
QuantAbundanceAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

30,464 signal articles · 149 in last 24h · 154,187 total before filter · latest 1h ago
149last 24h
874last 7d
144● bullish (7d)
96● bearish (7d)
214publishers
AllMacro211Earnings108M&A125Regulatory21Product21Analyst18
✕ clear all filtersticker: TGTSentiment:bullishneutralbearish✓ showing all (incl. clickbait)
Jim Cramer Says “Target’s Doing Better than Walmart Right Now”
Insider Monkey9d agoneutral
Jim Cramer Says “Target’s Doing Better than Walmart Right Now”

Inquiring about Walmart Inc. (NASDAQ:WMT) on September 10, a caller asked if they should “keep it.” Mad Money host Jim Cramer replied: I got to tell you, this one is a short and long-term, okay? Short-term, I think I know what Walmart’s doing. I think that they’re letting their customers have a big break. They’re […]

Is eBay Stock Worth The Ride?
Trefis9d agoneutral
Is eBay Stock Worth The Ride?

eBay (EBAY) has gained 5.4% over the past five trading days while the S&P 500 fell 1.3%. A stock rising in a falling market pulls money in. Five days say nothing about what a holding does to your money over the years you would own it. eBay's longer-term record presents a more mixed risk-adjusted picture.

Should You Buy Adobe Stock At $260?
Trefis9d agobullish
Should You Buy Adobe Stock At $260?

Adobe (ADBE) reported a record fiscal Q3 2026 and raised its fiscal 2026 revenue and earnings targets. Revenue rose 13% as reported to $6.76 billion, above the $6.70 billion the company had guided. But the key figure that did not move is the one to hold the quarter against: the fiscal 2026 target for growth in ending annualized recurring revenue, or ARR, still 10.2.

Attack of the Clones Speeds Up CVS Strategy
The Wall Street Journal9d agoneutral
Attack of the Clones Speeds Up CVS Strategy

“No, I don’t think so,” answered Joon Sung Park, co-founder and CEO at “digital twin” startup Simile, on the opening day of the Leadership Institute’s WSJ Technology Council Summit yesterday. Twins created with Simile are currently helping CVS Health make decisions more quickly and confidently, executives said as part of the same discussion. When the pharmacy and insurance company wanted to encourage adoption of lower-cost biologic drug alternatives, twins of the consumer pool suggested that people wanted to hear recommendations from their healthcare providers, said Tilak Mandadi, executive vice president of ventures and chief experience and technology officer at CVS Health.

Target Stock Option Trade Targets a Price of $170 by Nov 20th
Barchart9d agoneutral
Target Stock Option Trade Targets a Price of $170 by Nov 20th

A bullish diagonal spread is an advanced option trade and generally not suitable for beginners, but it can have its place within an option portfolio. It is a bullish strategy that benefits from time decay and is best placed when volatility is low, such as the current conditions.

Target Names New CMO
MediaPost10d agoneutral
Target Names New CMO

The retailer hires Mark Weinstein, Hilton's CMO, to fill the vacant role as it continues to build its comeback strategy,

Jim Cramer Highlights Affirm (AFRM) and Its Strong Merchant Network
Insider Monkey12d agoneutral
Jim Cramer Highlights Affirm (AFRM) and Its Strong Merchant Network

During the September 8 episode of Mad Money, examining consumer demand and macroeconomic pressures surrounding Affirm Holdings, Inc. (NASDAQ:AFRM), Jim Cramer commented: How about the buy now, pay later business that’s Affirm? Max Levchin’s company has 28 million active customers. Affirm has a, it’s got a who’s who of partners including the biggest Amazon, Costco, […]

Walmart and Target’s Shelves are Becoming a Battleground for Budget-Conscious Shoppers
Insider Monkey13d agoneutral
Walmart and Target’s Shelves are Becoming a Battleground for Budget-Conscious Shoppers

Shelf placement is becoming an increasingly important competitive weapon at Walmart Inc. (NYSE:WMT) and Target Corporation (NYSE:TGT). Haleon, the company behind Sensodyne, Advil, and Centrum, has negotiated more prominent positions at the two retailers by offering lower prices, stronger promotions, exclusive products, and other improved commercial terms. The strategy appears to be benefiting Haleon, whose […]